AzTrials
AzTrials

Microvascular AnginaEYE-NOCANCT06692751

The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).

An observational study of Microvascular Angina, run by Centre Hospitalier Universitaire Dijon at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Microvascular angina is thought to affect around 112 million patients worldwide. However, this figure is underestimated due to the difficulty of making the diagnosis. It is a pathology caused by an alteration in the microcirculation of the heart muscle, which is not detectable on a standard coronary angiogram. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Microvascular Angina
What is being tested?
Blood sampling, Ophthalmological examination and angina severity questionnaire
Type of treatment
Surgery or procedure
How many people
52 participants
Where
1 siteFrance
Study dates
13 Nov 2024to Nov 2029
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients treated at Dijon University Hospital, who received an IMR measurement as part of INOCA

Who may be able to join

  • Patients managed at Dijon University Hospital, having had an IMR measurement as part of INOCA during a coronary angiographic examination, consecutively includible, without angiographically or functionally significant coronary epicardial lesion (FFR < 0.80) explaining the clinical picture (= INOCA)
  • Person having given oral consent
  • Adult

Who cannot join

  • Person not affiliated or not benefiting from a social security scheme
  • Person subject to a legal protection measure (curatorship, guardianship) or a safeguard of justice measure
  • Pregnant or breast-feeding women
  • An adult incapable or unable to give consent
  • Person with macular or retinal pathology, or severe bilateral myopia
  • Person with genetic or idiopathic cardiomyopathy (dilated, hypertrophic or restrictive cardiomyopathy)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • CHU Dijon Bourgogne

    Dijon, 21000

    Pierre GUILLEMINOT, 0380293031, pierre.guilleminot@chu-dijon.fr

    Recruiting

Other trials in France

About this study

Microvascular angina is thought to affect around 112 million patients worldwide. However, this figure is underestimated due to the difficulty of making the diagnosis. It is a pathology caused by an alteration in the microcirculation of the heart muscle, which is not detectable on a standard coronary angiogram.

In view of its prognostic, therapeutic and medico-economic value, scientific societies currently recommend invasive measurement of the microcirculatory resistance index (MRI) to diagnose microvascular angina, in the absence of significant lesions on coronary angiography.

Read more

Several research teams, including our own, have shown that cardiovascular risk is associated with alterations in the vascularization of the small vessels (microcirculation) of the retina. Unlike the study of cardiac vessels, the study of retinal microcirculation using fundus photography (OCT-A) is simple, rapid, non-invasive and inexpensive. It appears to be an interesting alternative to the measurement of IMR for the diagnosis of microvascular angina.

This hypothesis has never yet been tested. The demonstration of an association between a decrease in retinal vascular density measured by OCT-A and an alteration in coronary microvascular function measured by IMR would pave the way for a completely non-invasive diagnosis of patients.

This is an observational, cohort, prospective, single-center pilot study comparing people who have received an IMR measurement as part of INOCA.

It is planned to include 158 participants. The overall follow-up period for each patient in the research is 12 months.

In routine care, IMR is measured during coronary angiography in patients presenting with ischemia on a non-invasive test and/or stress symptoms such as angina or dyspnea, for whom coronary angiography does not reveal any significant epicardial lesion.

Following this examination, two groups will be formed: a group with an IMR<25 and a group with an IMR≥25. Clinically, the study aims to determine the potential role of retinal OCT-A as a non-invasive examination for the diagnosis and/or follow-up of INOCA.

Being tested
Blood sampling, Ophthalmological examination, angina severity questionnaire
Medical subject headings
Microvascular Angina

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood samplingBiological

    2 tubes of 5 mL

  • Ophthalmological examinationProcedure or surgery

    angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.

    An optional 20-30 minute WLR may be offered following OCT-A.

  • angina severity questionnaireOther

    at inclusion, 3 months and 1 year Estimated filling time: 2 minutes

Study groups in NCT06692751
Study groupRoleWhat they receive
IMR<25People without microvascular angina
Receives: Biological: Blood sampling; Procedure: Ophthalmological examination; Other: angina severity questionnaire
IMR≥25People with microvascular angina
Receives: Biological: Blood sampling; Procedure: Ophthalmological examination; Other: angina severity questionnaire

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Retinal vascular density by "inner vessel length density" determined by OCT-A

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2024
  2. Study start13 Nov 2024
  3. Primary completionNov 2029 (estimated)
  4. Study completionNov 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
52 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06692751
Sponsor's protocol ID
POMMIER J'InvEST-I 2023
Acronym
EYE-NOCA
Status last verified
Oct 2026
First submitted
15 Nov 2024
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in